Share-based Payment Arrangement, Expense of LUMOS PHARMA, INC. from 31 Dec 2010 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
LUMOS PHARMA, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2024.
  • LUMOS PHARMA, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2024 was $379,000, a 32% decline year-over-year.
  • LUMOS PHARMA, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2024 was $1,870,000, a 22% decline year-over-year.
  • LUMOS PHARMA, INC. annual Share-based Payment Arrangement, Expense for 2023 was $2,322,000, a 0.09% increase from 2022.
  • LUMOS PHARMA, INC. annual Share-based Payment Arrangement, Expense for 2022 was $2,320,000, a 19% decline from 2021.
  • LUMOS PHARMA, INC. annual Share-based Payment Arrangement, Expense for 2021 was $2,879,000, a 168% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

LUMOS PHARMA, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $1,870,000 $379,000 -$180,000 -32% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $2,050,000 $387,000 -$266,000 -41% 01 Apr 2024 30 Jun 2024 10-Q 02 Aug 2024 2024 Q2
Q1 2024 $2,316,000 $580,000 -$6,000 -1% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $2,322,000 $524,000 -$63,000 -11% 01 Oct 2023 31 Dec 2023 10-K 07 Mar 2024 2023 FY
Q3 2023 $2,385,000 $559,000 -$34,000 -5.7% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $2,419,000 $653,000 +$78,000 +14% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024 2024 Q2
Q1 2023 $2,341,000 $586,000 +$21,000 +3.7% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $2,320,000 $587,000 +$93,000 +19% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q3 2022 $2,227,000 $593,000 +$103,000 +21% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $2,124,000 $575,000 -$271,000 -32% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $2,395,000 $565,000 -$484,000 -46% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q4 2021 $2,879,000 $494,000 +$176,000 +55% 01 Oct 2021 31 Dec 2021 10-K 07 Mar 2023 2022 FY
Q3 2021 $2,703,000 $490,000 +$185,000 +61% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $2,518,000 $846,000 +$572,000 +209% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $1,946,000 $1,049,000 +$872,000 +493% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $1,074,000 $318,000 +$271,000 +577% 01 Oct 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
Q3 2020 $803,000 $305,000 +$261,000 +593% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2021 2021 Q3
Q2 2020 $542,000 $274,000 +$234,000 +585% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $308,000 $177,000 +$129,000 +269% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $179,000 $47,000 -$3,453,000 -99% 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $3,632,000 $44,000 -$4,556,000 -99% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $8,188,000 $40,000 -$4,160,000 -99% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2020 Q2
Q1 2019 $12,348,000 $48,000 -$4,752,000 -99% 01 Jan 2019 31 Mar 2019 10-Q 02 Jun 2020 2020 Q1
Q4 2018 $17,100,000 $3,500,000 -$100,000 -2.8% 01 Oct 2018 31 Dec 2018 10-K 03 Mar 2020 2019 FY
Q3 2018 $17,200,000 $4,600,000 +$200,000 +4.5% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $17,000,000 $4,200,000 -$400,000 -8.7% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $17,400,000 $4,800,000 -$1,100,000 -19% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $18,500,000 $3,600,000 $0 0% 01 Oct 2017 31 Dec 2017 10-K 03 Mar 2020 2019 FY
Q3 2017 $18,500,000 $4,400,000 +$500,000 +13% 01 Jul 2017 30 Sep 2017 10-Q 02 Nov 2018 2018 Q3
Q2 2017 $18,000,000 $4,600,000 +$100,000 +2.2% 01 Apr 2017 30 Jun 2017 10-Q 06 Aug 2018 2018 Q2
Q1 2017 $17,900,000 $5,900,000 +$1,200,000 +26% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $16,700,000 $3,600,000 +$100,000 +2.9% 01 Oct 2016 31 Dec 2016 10-K 05 Mar 2019 2018 FY
Q3 2016 $16,600,000 $3,900,000 +$600,000 +18% 01 Jul 2016 30 Sep 2016 10-Q 03 Nov 2017 2017 Q3
Q2 2016 $16,000,000 $4,500,000 -$1,400,000 -24% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $17,400,000 $4,700,000 +$1,500,000 +47% 01 Jan 2016 31 Mar 2016 10-Q 05 May 2017 2017 Q1
Q4 2015 $15,900,000 $3,500,000 +$1,800,000 +106% 01 Oct 2015 31 Dec 2015 10-K 05 Mar 2018 2017 FY
Q3 2015 $14,100,000 $3,300,000 $0 0% 01 Jul 2015 30 Sep 2015 10-Q 08 Nov 2016 2016 Q3
Q2 2015 $14,100,000 $5,900,000 +$4,400,000 +293% 01 Apr 2015 30 Jun 2015 10-Q 05 Aug 2016 2016 Q2
Q1 2015 $9,700,000 $3,200,000 +$1,100,000 +52% 01 Jan 2015 31 Mar 2015 10-Q 29 Apr 2016 2016 Q1
Q4 2014 $8,600,000 $1,700,000 +$466,000 +38% 01 Oct 2014 31 Dec 2014 10-K 06 Mar 2017 2016 FY
Q3 2014 $8,134,000 $3,300,000 +$2,200,000 +200% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3
Q2 2014 $5,934,000 $1,500,000 +$400,000 +36% 01 Apr 2014 30 Jun 2014 10-Q 06 Aug 2015 2015 Q2
Q1 2014 $5,534,000 $2,100,000 +$1,134,000 +117% 01 Jan 2014 31 Mar 2014 10-Q/A 24 Aug 2015 2015 Q1
Q4 2013 $4,400,000 $1,234,000 +$599,000 +94% 01 Oct 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
Q3 2013 $3,801,000 $1,100,000 +$471,000 +75% 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014 2014 Q3
Q2 2013 $3,330,000 $1,100,000 -$100,000 -8.3% 01 Apr 2013 30 Jun 2013 10-Q 05 Aug 2014 2014 Q2
Q1 2013 $3,430,000 $966,000 +$230,000 +31% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014 2014 Q1
Q4 2012 $3,200,000 $635,000 01 Oct 2012 31 Dec 2012 10-K 16 Mar 2015 2014 FY
Q3 2012 $629,000 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013 2013 Q3
Q2 2012 $1,200,000 01 Apr 2012 30 Jun 2012 10-Q 08 Aug 2013 2013 Q2
Q1 2012 $736,000 01 Jan 2012 31 Mar 2012 10-Q 08 May 2013 2013 Q1

LUMOS PHARMA, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $2,322,000 +$2,000 +0.09% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2024 2023 FY
2022 $2,320,000 -$559,000 -19% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 $2,879,000 +$1,805,000 +168% 01 Jan 2021 31 Dec 2021 10-K 07 Mar 2023 2022 FY
2020 $1,074,000 +$895,000 +500% 01 Jan 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
2019 $179,000 -$16,921,000 -99% 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
2018 $17,100,000 -$1,400,000 -7.6% 01 Jan 2018 31 Dec 2018 10-K 03 Mar 2020 2019 FY
2017 $18,500,000 +$1,800,000 +11% 01 Jan 2017 31 Dec 2017 10-K 03 Mar 2020 2019 FY
2016 $16,700,000 +$800,000 +5% 01 Jan 2016 31 Dec 2016 10-K 05 Mar 2019 2018 FY
2015 $15,900,000 +$7,300,000 +85% 01 Jan 2015 31 Dec 2015 10-K 05 Mar 2018 2017 FY
2014 $8,600,000 +$4,200,000 +95% 01 Jan 2014 31 Dec 2014 10-K 06 Mar 2017 2016 FY
2013 $4,400,000 +$1,200,000 +38% 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
2012 $3,200,000 +$700,000 +28% 01 Jan 2012 31 Dec 2012 10-K 16 Mar 2015 2014 FY
2011 $2,500,000 +$1,000,000 +67% 01 Jan 2011 31 Dec 2011 10-K 12 Mar 2014 2013 FY
2010 $1,500,000 01 Jan 2010 31 Dec 2010 10-K 15 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.